What You Should Know
- The Funding: New York-based Jimini Health has secured a massive $17M in seed funding (bringing its total raised to over $25M). The round includes heavyweights like M13, Town Hall Ventures, and Zetta Venture Partners, and features backing from former CMS Acting Administrator Andy Slavitt.
- The Team: Jimini brings serious enterprise pedigree. CEO Luis Voloch previously co-founded Immunai (valued at $1B+), and the executive suite includes former leadership from Talkspace, Guardant Health, and Ribbon Health, plus advisory backing from Moderna co-founder Robert Langer.
The Crisis of Unsupervised AI
While health system CIOs debate the merits of using generative AI for medical coding and back-office administration, the patients have already moved on. Over 5.4 million young adults in the U.S. are actively using consumer AI chatbots for mental health advice. Every single week, over one million people have conversations with ChatGPT that include explicit indicators of suicidal planning.
These consumer chatbots were never designed to handle severe psychiatric triage. They hallucinate, they lack clinical guardrails, and crucially, they operate completely outside the visibility of a licensed provider. Following high-profile wrongful death lawsuits against platforms like Character.AI, the message to the behavioral health industry is clear: patients are going to use AI for mental health support whether you sanction it or not.
“When 1 million people a week are discussing suicide with a product that was never designed to handle it, that’s not an edge case, it’s a systemic gap,” noted Morgan Blumberg, Partner at M13. “Jimini is building the clinical infrastructure this category has never had: real supervision, real clinicians, real oversight.”
Introducing “Sage”: The Guardrailed Care Team Member
To understand why investors are pouring over $25M into a seed-stage company, you have to look at Jimini’s architectural philosophy. They are not building an app store chatbot. Their platform, Sage, is designed to be deeply integrated into the Electronic Health Record (EHR) of large, multi-site behavioral health organizations. Sage engages directly with the patient between appointments, providing continuous, AI-supported engagement.
However, unlike an open-ended Large Language Model (LLM), Sage does not improvise. It closely follows the specific care plan designed by the human clinician. It leaves all diagnostics and care decisions to the human team, and every single interaction between the patient and Sage is visible to the supervising provider. To prove the model’s safety, Jimini actually operates its own clinic, employing full-time licensed clinicians who treat real patients on the platform before any model update is deployed nationwide.
Riding the CMS/FDA Tailwind
“As CMS and other payers create new pathways for technology-enabled care, the stakes for getting AI right in behavioral health have never been higher,” said Andy Slavitt, Jimini investor and former Acting Administrator of CMS.
From an enterprise strategy perspective, Jimini’s timing is impeccable. The December 2025 launch of the FDA and CMS joint ACCESS and TEMPO programs signaled a massive regulatory green light for tech-heavy care models, provided they keep clinicians in the loop.
Hospital operators and behavioral health clinics are currently staring down a massive liability risk if their patients seek out unverified AI therapy in the wild. By offering a structured, reimbursement-ready platform that natively integrates with existing clinical workflows, Jimini Health provides a safe harbor. If CEO Luis Voloch and his veteran leadership team can successfully scale this across major health systems, they won’t just be building another AI company; they will be defining the universal standard of care for responsible, patient-facing clinical AI.
